Ocugen Inc. (OCGN): Price and Financial Metrics
OCGN Price/Volume Stats
| Current price | $0.95 | 52-week high | $1.98 |
| Prev. close | $0.89 | 52-week low | $0.52 |
| Day low | $0.90 | Volume | 11,083,700 |
| Day high | $1.01 | Avg. volume | 4,197,128 |
| 50-day MA | $0.74 | Dividend yield | N/A |
| 200-day MA | $0.85 | Market Cap | 278.28M |
OCGN Stock Price Chart Interactive Chart >
Ocugen Inc. (OCGN) Company Bio
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.
OCGN Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OCGN Price Returns
| 1-mo | 43.48% |
| 3-mo | 55.69% |
| 6-mo | 9.20% |
| 1-year | -45.09% |
| 3-year | -61.85% |
| 5-year | 280.15% |
| YTD | 18.01% |
| 2024 | 40.00% |
| 2023 | -55.77% |
| 2022 | -71.43% |
| 2021 | 148.63% |
| 2020 | 251.92% |